 |
|
Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal Cancer
Virgínia Piñol, MD;
Antoni Castells, MD;
Montserrat Andreu, MD;
Sergi Castellví-Bel, PhD;
Cristina Alenda, MD;
Xavier Llor, MD;
Rosa M. Xicola, PhD;
Francisco Rodríguez-Moranta, MD;
Artemio Payá, MD;
Rodrigo Jover, MD;
Xavier Bessa, MD; for the Gastrointestinal Oncology Group of the Spanish Gastroenterological Association
JAMA. 2005;293:1986-1994.
Context The selection of individuals for hereditary nonpolyposis colorectal cancer (HNPCC) genetic testing is challenging. Recently, the National Cancer Institute outlined a new set of recommendations, the revised Bethesda guidelines, for the identification of individuals with HNPCC who should be tested for microsatellite instability.
Objective To establish the most effective and efficient strategy for the detection of MSH2/MLH1 gene carriers.
Design, Setting, and Patients A prospective, multicenter, nationwide study (the EPICOLON study) in 20 hospitals in the general community in Spain of 1222 patients with newly diagnosed colorectal cancer between November 1, 2000, and October 31, 2001.
Interventions Microsatellite instability testing and MSH2/MLH1 immunostaining in all patients regardless of age, personal or family history, and tumor characteristics. Patients whose tumors exhibited microsatellite instability and/or lack of protein expression underwent MSH2/MLH1 germline testing.
Main Outcome Measures Effectiveness and efficiency of both microsatellite instability testing and immunostaining, either directly or previous selection of patients according to the revised Bethesda guidelines, were evaluated with respect to the presence of MSH2/MLH1 germline mutations.
Results Two hundred eighty-seven patients (23.5%) fulfilled the revised Bethesda guidelines. Ninety-one patients (7.4%) had a mismatch repair deficiency, with tumors exhibiting either microsatellite instability (n = 83) or loss of protein expression (n = 81). Germline testing identified 11 mutations (0.9%) in either MSH2 (7 cases) or MLH1 (4 cases) genes. Strategies based on either microsatellite instability testing or immunostaining previous selection of patients according to the revised Bethesda guidelines were the most effective (sensitivity, 81.8% and 81.8%; specificity, 98.0% and 98.2%; positive predictive value, 27.3% and 29.0%, respectively) to identify MSH2/MLH1 gene carriers. Logistic regression analysis confirmed the revised Bethesda guidelines as the most discriminating set of clinical parameters (odds ratio, 33.3; 95% confidence interval, 4.3-250; P = .001).
Conclusion The revised Bethesda guidelines constitute a useful approach to identify patients at risk for HNPCC. In patients fulfilling these criteria, both microsatellite instability testing and immunostaining are equivalent and highly effective strategies to further select those patients who should be tested for MSH2/MLH1 germline mutations.
Author Affiliations: Department of Gastroenterology, Institut de Malalties Digestives, Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (Drs Piñol, Castells, Castellví-Bel, and Rodríguez-Moranta); Department of Gastroenterology, Hospital del Mar, Barcelona (Drs Andreu and Bessa); Departments of Pathology (Drs Alenda and Payá) and Gastroenterology (Dr Jover), Hospital General Universitario de Alicante, Alicante; and Department of Gastroenterology, Hospital Universitari Germans Trias i Pujol, Badalona (Drs Llor and Xicola), Spain.
RELATED ARTICLES
Lower Cancer Incidence in Amsterdam-I Criteria Families Without Mismatch Repair Deficiency: Familial Colorectal Cancer Type X
Noralane M. Lindor, Kari Rabe, Gloria M. Petersen, Robert Haile, Graham Casey, John Baron, Steve Gallinger, Bharati Bapat, Melyssa Aronson, John Hopper, Jeremy Jass, Loic LeMarchand, John Grove, John Potter, Polly Newcomb, Jonathan P. Terdiman, Peggy Conrad, Gabriella Moslein, Richard Goldberg, Argyrios Ziogas, Hoda Anton-Culver, Mariza de Andrade, Kim Siegmund, Stephen N. Thibodeau, Lisa A. Boardman, and Daniela Seminara
JAMA. 2005;293(16):1979-1985.
ABSTRACT
| FULL TEXT
Progress in Genetic Testing, Classification, and Identification of Lynch Syndrome
Hans F. A. Vasen and C. Richard Boland
JAMA. 2005;293(16):2028-2030.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients
Balmana et al.
J. Med. Genet. 2008;45:557-563.
ABSTRACT
| FULL TEXT
Immunohistochemistry versus Microsatellite Instability Testing For Screening Colorectal Cancer Patients at Risk For Hereditary Nonpolyposis Colorectal Cancer Syndrome: Part I. The Utility of Immunohistochemistry
Shia
J. Mol. Diagn. 2008;10:293-300.
ABSTRACT
| FULL TEXT
Immunohistochemistry versus Microsatellite Instability Testing for Screening Colorectal Cancer Patients at Risk for Hereditary Nonpolyposis Colorectal Cancer Syndrome: Part II. The Utility of Microsatellite Instability Testing
Zhang
J. Mol. Diagn. 2008;10:301-307.
ABSTRACT
| FULL TEXT
Risk Quantification for Carrying Mutations in Lynch Syndrome Genes
Balmana et al.
Am Soc Clin Oncol Ed Book 2008;2008:59-64.
ABSTRACT
| FULL TEXT
How Should Women With Early-Onset Endometrial Cancer Be Evaluated for Lynch Syndrome?
Kauff
JCO 2007;25:5143-5146.
FULL TEXT
New Issues in Genetic Counseling of Hereditary Colon Cancer
Lynch
Clin. Cancer Res. 2007;13:6857s-6861s.
ABSTRACT
| FULL TEXT
The genetics of hereditary colon cancer
Rustgi
Genes Dev. 2007;21:2525-2538.
ABSTRACT
| FULL TEXT
Who Should Be Sent for Genetic Testing in Hereditary Colorectal Cancer Syndromes?
Lynch et al.
JCO 2007;25:3534-3542.
ABSTRACT
| FULL TEXT
Association of the ARLTS1 Cys148Arg variant with sporadic and familial colorectal cancer
Castellvi-Bel et al.
Carcinogenesis 2007;28:1687-1691.
ABSTRACT
| FULL TEXT
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
Vasen et al.
J. Med. Genet. 2007;44:353-362.
ABSTRACT
| FULL TEXT
TGF-{beta} signaling alterations and susceptibility to colorectal cancer
Xu and Pasche
Hum Mol Genet 2007;16:R14-R20.
ABSTRACT
| FULL TEXT
Toward a Consensus in Molecular Diagnosis of Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome)
Lynch et al.
JNCI J Natl Cancer Inst 2007;99:261-263.
FULL TEXT
Performance of Different Microsatellite Marker Panels for Detection of Mismatch Repair-Deficient Colorectal Tumors
Xicola et al.
JNCI J Natl Cancer Inst 2007;99:244-252.
ABSTRACT
| FULL TEXT
Identification of mismatch repair gene mutations in young patients with colorectal cancer and in patients with multiple tumours associated with hereditary non-polyposis colorectal cancer
Niessen et al.
Gut 2006;55:1781-1788.
ABSTRACT
| FULL TEXT
Detection of BRAF V600E Mutation in Colorectal Cancer: Comparison of Automatic Sequencing and Real-Time Chemistry Methodology
Benlloch et al.
J. Mol. Diagn. 2006;8:540-543.
ABSTRACT
| FULL TEXT
Prediction of MLH1 and MSH2 mutations in Lynch syndrome.
Balmana et al.
JAMA 2006;296:1469-1478.
ABSTRACT
| FULL TEXT
Predicting and preventing hereditary colorectal cancer.
Ford and Whittemore
JAMA 2006;296:1521-1523.
FULL TEXT
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
Jover et al.
Gut 2006;55:848-855.
ABSTRACT
| FULL TEXT
Cyclooxygenase 2 expression in colorectal cancer with DNA mismatch repair deficiency.
Castells et al.
Clin. Cancer Res. 2006;12:1686-1692.
ABSTRACT
| FULL TEXT
Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis
Chao and Lipkin
Nucleic Acids Res 2006;34:840-852.
ABSTRACT
| FULL TEXT
Differential Features of Colorectal Cancers Fulfilling Amsterdam Criteria without Involvement of the Mutator Pathway
Llor et al.
Clin. Cancer Res. 2005;11:7304-7310.
ABSTRACT
| FULL TEXT
Revised Bethesda Guidelines Useful in Searching for HNPCC Mutations
JWatch Gastroenterology 2005;2005:4-4.
FULL TEXT
Progress in Genetic Testing, Classification, and Identification of Lynch Syndrome
Vasen and Boland
JAMA 2005;293:2028-2030.
FULL TEXT
|
